Skip to content
Get alerts
GovInfoNow
Use caution Drug recall · FDA · Published August 25, 2014

Taro Recalls Warfarin 2mg Tablets Due to Content Uniformity Failure

Taro Pharmaceuticals recalls specific lots of Warfarin Sodium 2mg tablets because they failed content uniformity specifications. Check your bottle's lot number.

Plain-English summary generated from official FDA data by GovInfoNow · Published by Carlos Caban · How we make summaries

🇺🇸 FDA recall #D-1584-2014DrugTaro Pharmaceuticals ›
Take action

Contact the company

Recalling firmTaro Pharmaceuticals U.S.A., Inc.3 Skyline Dr · Hawthorne, NY 10532-2174
✎ GovInfoNow plain-language explainer

Taro Pharmaceuticals is recalling Warfarin Sodium Tablets, USP Crystalline, 2 mg in 100 and 1000 tablet bottles due to failed content uniformity specifications. This means the amount of active ingredient in each tablet may not be consistent with what is listed on the label. The recall affects specific lots distributed in the United States. Read more at govinfonow.com/recall/45897-taro-pharmaceuticals-u-s-a-inc-recalls-warfarin-sodium-tablets.

Source Summary by GovInfoNow · govinfonow.com/recall/45897-taro-pharmaceuticals-u-s-a-inc-recalls-warfarin-sodium-tablets · Updated October 12, 2026 · FDA enforcement record: FDA #D-1584-2014

Cite this page

“Taro Recalls Warfarin 2mg Tablets Due to Content Uniformity Failure.” GovInfoNow, updated October 12, 2026. https://govinfonow.com/recall/45897-taro-pharmaceuticals-u-s-a-inc-recalls-warfarin-sodium-tablets. Based on FDA recall #D-1584-2014 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1584-2014%22&limit=1).

The FDA announced on August 25, 2014, that Taro Pharmaceuticals U.S.A., Inc. voluntarily recalled Warfarin Sodium Tablets, USP Crystalline, 2 mg due to failed content uniformity specifications. The recall affects 1396 bottles distributed in the United States.

How to tell if you have it

  • Brand: Taro Pharmaceuticals
  • Product: Warfarin Sodium Tablets 2 mg
  • NDC: 51672-4028-1 (100 Tablet Bottle)
  • NDC: 51672-4028-3 (1000 Tablet Bottle)
  • Lot #: 149400, Expiry: January 2016
  • Lot #: 149649, Expiry: January 2016

The hazard

The recalled Warfarin Sodium Tablets failed content uniformity specifications. The FDA classified this as a Class III recall.

Context

GovInfoNow's records show Taro Pharmaceuticals U.S.A., Inc. has 20 other recalls on record since 2012-11-21. Other recent recalls of similar products include Taro Hydrocortisone Otic Solution (2024-08-07), Taro Clotrimazole-Betamethasone (2022-02-25), and Taro Clobetasol Ointment (2021-12-15). Other recent recalls of similar products include Taro Children's Ibuprofen (2026-03-02), SUN PHARMA /TARO Lidocaine Ointment 5% (2026-08-31), and Lupin Clobetasol Cream (2026-08-03).

How to tell if you have this one

Check your bottle for NDC 51672-4028-1 (100 tablets) or NDC 51672-4028-3 (1000 tablets). Verify the lot number is either 149400 or 149649, both with an expiry date of January 2016. The product was distributed in the United States, including OH, HI, NH, MS, IL, TX, and CA.

  • Brand
    Taro Pharmaceuticals
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Your Bottle

    Verify if your Warfarin Sodium 2mg bottle matches the recalled NDCs and lot numbers (149400 or 149649).

  2. Contact Your Pharmacist

    Speak with your pharmacist or healthcare provider to determine if you have the recalled product and how to proceed.

Where it went and when

Where it was distributed

Distributed in 7 states.

Alaska: not listedAKMaine: not listedMEVermont: not listedVTNew Hampshire: yesNHWashington: not listedWAIdaho: not listedIDMontana: not listedMTNorth Dakota: not listedNDMinnesota: not listedMNIllinois: yesILWisconsin: not listedWIMichigan: not listedMINew York: not listedNYRhode Island: not listedRIMassachusetts: not listedMAOregon: not listedORNevada: not listedNVWyoming: not listedWYSouth Dakota: not listedSDIowa: not listedIAIndiana: not listedINOhio: yesOHPennsylvania: not listedPANew Jersey: not listedNJConnecticut: not listedCTCalifornia: yesCAUtah: not listedUTColorado: not listedCONebraska: not listedNEMissouri: not listedMOKentucky: not listedKYWest Virginia: not listedWVVirginia: not listedVAMaryland: not listedMDDelaware: not listedDEArizona: not listedAZNew Mexico: not listedNMKansas: not listedKSArkansas: not listedARTennessee: not listedTNNorth Carolina: not listedNCSouth Carolina: not listedSCDistrict of Columbia: not listedDCOklahoma: not listedOKLouisiana: not listedLAMississippi: yesMSAlabama: not listedALGeorgia: not listedGAHawaii: yesHITexas: yesTXFlorida: not listedFL

FDA distribution: “United States including: OH, HI, NH, MS, IL, TX, CA.” States read from FDA’s own wording; “not listed” means the notice does not name it.

States: California, Hawaii, Illinois, Mississippi, New Hampshire, Ohio, Texas.

Recall timeline

FDA terminated this recall 3.7 years after the firm started it.

1. Firm started the recall: Aug 25, 201412. FDA classified it Class III: Sep 12, 201423. Published in FDA’s Enforcement Report: Sep 24, 201434. FDA terminated the recall: May 18, 2018420142018
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Taro Recalls Children's Ibuprofen Due to Foreign Substance
TaroSUN PHARMA /TARO Lidocaine Ointment 5% Recall: Failed Content Uniformity
SUN PHARMA /TAROLupin Clobetasol Cream Recall: Failed Content Uniformity
Lupin PharmaceuticalsAmerican Health Packaging Recalls Metoclopramide Tablets Due to Foreign Drug Presence
American Health PackagingTeva Recalls Metoclopramide Tablets Due to Foreign Contaminants
Teva Pharmaceuticals USA, Inc

Latest drug recalls

Preferred Pharmaceuticals, Inc. recalls Lidocaine Ointment USP, 5% (Generic for Xylocaine), packaged in a 50 g jar, Rx only, Mfg: Taro Pharmaceuticals U.S.A.,
Preferred Pharmaceuticals · September 28, 2026SUN PHARMACEUTICAL INDUSTRIES INC recalls Tretinoin Cream USP, 0.05%, 45 g tube, Manufactured for: Northstar Rx LLC, Memphis, TN 38141, Manufactured by: Taro
Northstar Rx · September 25, 2026Apothecary Pharma LLC recalls Tirzepatide Injection, 18mg/mL, 4 mL Sterile Multi-Dose Vial, Rx only, Apothecary Pharma, LLC, 1913 Evans Road, Cary,
Apothecary Pharma · September 24, 2026Apotex Corp. recalls Paroxetine Extended-Release Tablets, 37.5mg, 30-count bottle, Rx only, Manufactured by: Apotex Inc., Toronto, Ontario,
Apotex · September 23, 2026Cipla USA, Inc. recalls Fosfomycin Tromethamine Granules for Oral Solution, (Equivalent to 3 Grams of Fosfomycin), 1 Single-Dose Sachet, Rx
Cipla USA · September 18, 2026Ajanta Pharma USA Inc recalls Ranolazine Extended-Release Tablets, 1000 mg, 60-count bottle, Rx Only, Marketed by: Ajanta Pharma USA Inc.,
Ajanta Pharma · September 17, 2026

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-1584-2014 (August 25, 2014) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1584-2014 to see it in context.
  • Plain-language summary written by qwen3.6:35b-a3b on October 12, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA